{
    "id": 14628,
    "fullName": "CSF3R T618I",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "CSF3R T618I lies within the extracellular domain proximal to the transmembrane domain of the Csf3r protein (PMID: 23656643). T618I confers a gain of function to the Csf3r protein as demonstrated by increased proliferation and increased downstream Jak-Stat signaling in transformed cells in culture (PMID: 23656643).",
            "references": [
                {
                    "id": 3951,
                    "pubMedId": 23656643,
                    "title": "Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23656643"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1441,
        "geneSymbol": "CSF3R",
        "terms": [
            "CSF3R",
            "CD114",
            "GCSFR",
            "SCN7"
        ]
    },
    "variant": "T618I",
    "createDate": "11/30/2015",
    "updateDate": "12/01/2015",
    "referenceTranscriptCoordinates": {
        "id": 121596,
        "transcript": "NM_000760",
        "gDna": "chr1:g.36467833G>A",
        "cDna": "c.1853C>T",
        "protein": "p.T618I",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4654,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Jakafi (ruxolitinib) reduced colony formation of cells expressing CSF3R T618I in culture (PMID: 26475333, PMID: 29977015).",
            "molecularProfile": {
                "id": 14885,
                "profileName": "CSF3R T618I"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4663,
                    "pubMedId": 26475333,
                    "title": "The Colony-Stimulating Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26475333"
                },
                {
                    "id": 11863,
                    "pubMedId": 29977015,
                    "title": "Time resolved quantitative phospho-tyrosine analysis reveals Bruton's Tyrosine kinase mediated signaling downstream of the mutated granulocyte-colony stimulating factor receptors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29977015"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19734,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed hematologic cells expressing CSF3R T618I demonstrated resistance to treatment with Sprycel (dasatinib) in culture (PMID: 28031554).",
            "molecularProfile": {
                "id": 14885,
                "profileName": "CSF3R T618I"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11456,
                    "pubMedId": 28031554,
                    "title": "Enhanced MAPK signaling is essential for CSF3R-induced leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28031554"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14962,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, cells expressing CSF3R T618I were sensitive to treatment with Imbruvica (ibrutinib) in culture, demonstrating a reduced cell proliferation (PMID: 29977015).",
            "molecularProfile": {
                "id": 14885,
                "profileName": "CSF3R T618I"
            },
            "therapy": {
                "id": 768,
                "therapyName": "Ibrutinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11863,
                    "pubMedId": 29977015,
                    "title": "Time resolved quantitative phospho-tyrosine analysis reveals Bruton's Tyrosine kinase mediated signaling downstream of the mutated granulocyte-colony stimulating factor receptors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29977015"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14965,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the combination of Imbruvica (ibrutinib) and Jakafi (ruxolitinib) resulted in a synergistic effect in cells expressing CSF3R T618I, demonstrating greater decreased cell viability as compared to either agent alone (PMID: 29977015).",
            "molecularProfile": {
                "id": 14885,
                "profileName": "CSF3R T618I"
            },
            "therapy": {
                "id": 4768,
                "therapyName": "Ibrutinib + Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 11863,
                    "pubMedId": 29977015,
                    "title": "Time resolved quantitative phospho-tyrosine analysis reveals Bruton's Tyrosine kinase mediated signaling downstream of the mutated granulocyte-colony stimulating factor receptors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29977015"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19739,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed hematologic cells co-expressing CSF3R T618I and CSF3R W791* were resistant to treatment with Jakafi (ruxolitinib) in culture, demonstrating decreased cell survival (PMID: 28031554).",
            "molecularProfile": {
                "id": 34474,
                "profileName": "CSF3R T618I CSF3R W791*"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11456,
                    "pubMedId": 28031554,
                    "title": "Enhanced MAPK signaling is essential for CSF3R-induced leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28031554"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19738,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed hematologic cells co-expressing CSF3R T618I and CSF3R W791* were resistant to treatment with AZD1480 in culture (PMID: 28031554).",
            "molecularProfile": {
                "id": 34474,
                "profileName": "CSF3R T618I CSF3R W791*"
            },
            "therapy": {
                "id": 652,
                "therapyName": "AZD1480",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11456,
                    "pubMedId": 28031554,
                    "title": "Enhanced MAPK signaling is essential for CSF3R-induced leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28031554"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19740,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed hematologic cells co-expressing CSF3R T618I and CSF3R W791* were resistant to treatment with Sprycel (dasatinib) in culture (PMID: 28031554).",
            "molecularProfile": {
                "id": 34474,
                "profileName": "CSF3R T618I CSF3R W791*"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11456,
                    "pubMedId": 28031554,
                    "title": "Enhanced MAPK signaling is essential for CSF3R-induced leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28031554"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19742,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed hematologic cells co-expressing CSF3R T618I and CSF3R Q741* were resistant to treatment with Sprycel (dasatinib) in culture (PMID: 28031554).",
            "molecularProfile": {
                "id": 34475,
                "profileName": "CSF3R T618I CSF3R Q741*"
            },
            "therapy": {
                "id": 717,
                "therapyName": "Dasatinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11456,
                    "pubMedId": 28031554,
                    "title": "Enhanced MAPK signaling is essential for CSF3R-induced leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28031554"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19737,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed hematologic cells co-expressing CSF3R T618I and CSF3R Q741* were resistant to treatment with AZD1480 in culture (PMID: 28031554).",
            "molecularProfile": {
                "id": 34475,
                "profileName": "CSF3R T618I CSF3R Q741*"
            },
            "therapy": {
                "id": 652,
                "therapyName": "AZD1480",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11456,
                    "pubMedId": 28031554,
                    "title": "Enhanced MAPK signaling is essential for CSF3R-induced leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28031554"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 19741,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed hematologic cells co-expressing CSF3R T618I and CSF3R Q741* were resistant to treatment with Jakafi (ruxolitinib) in culture (PMID: 28031554).",
            "molecularProfile": {
                "id": 34475,
                "profileName": "CSF3R T618I CSF3R Q741*"
            },
            "therapy": {
                "id": 907,
                "therapyName": "Ruxolitinib",
                "synonyms": null
            },
            "indication": {
                "id": 2531,
                "name": "hematologic cancer",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 11456,
                    "pubMedId": 28031554,
                    "title": "Enhanced MAPK signaling is essential for CSF3R-induced leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/28031554"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 14885,
            "profileName": "CSF3R T618I",
            "profileTreatmentApproaches": [
                {
                    "id": 19892,
                    "name": "JAK Inhibitor (Pan) - ATP competitive",
                    "profileName": "CSF3R T618I"
                }
            ]
        },
        {
            "id": 34474,
            "profileName": "CSF3R T618I CSF3R W791*",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 34475,
            "profileName": "CSF3R T618I CSF3R Q741*",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 121599,
            "transcript": "XM_011540748",
            "gDna": "chr1:g.36467833G>A",
            "cDna": "c.1853C>T",
            "protein": "p.T618I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 121597,
            "transcript": "NM_156039",
            "gDna": "chr1:g.36467833G>A",
            "cDna": "c.1853C>T",
            "protein": "p.T618I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 121595,
            "transcript": "NM_172313",
            "gDna": "chr1:g.36467833G>A",
            "cDna": "c.1853C>T",
            "protein": "p.T618I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 121596,
            "transcript": "NM_000760",
            "gDna": "chr1:g.36467833G>A",
            "cDna": "c.1853C>T",
            "protein": "p.T618I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 121594,
            "transcript": "XM_011540749",
            "gDna": "chr1:g.36467833G>A",
            "cDna": "c.1853C>T",
            "protein": "p.T618I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 121593,
            "transcript": "XM_005270493",
            "gDna": "chr1:g.36467833G>A",
            "cDna": "c.1853C>T",
            "protein": "p.T618I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 121598,
            "transcript": "XM_017000370",
            "gDna": "chr1:g.36467833G>A",
            "cDna": "c.1853C>T",
            "protein": "p.T618I",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}